Study of damoctocog alfa pegol in children with hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how well a medicine called damoctocog alfa pegol (Jivi) works to prevent bleeding in children with hemophilia A. It will follow children who are already using this medicine or starting it, to see how effective it is in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have hemophilia A.
- The person must be between 7 and under 12 years old when joining.
- They must have been treated for hemophilia before (at least 50 times).
- No current inhibitor (a protein that blocks the clotting factor) or suspicion of one.
- If there was a previous inhibitor, they must have been on regular preventive treatment for at least 1 year.
- They must be using or starting the study medicine (damoctocog alfa pegol) for routine prevention.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is checking the safety of Jivi (a Factor VIII medicine) when used in normal medical care for people with hemophilia A in Korea. It is for anyone 12 or older who has used Factor VIII before or is starting Jivi as part of their regular treatment.
This study is looking at the safety and effectiveness of a factor VIII medicine called octocog alfa (used to treat bleeding) in men with severe hemophilia A in India. It will track how well the medicine works and any side effects during routine care.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.